Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention?

Cardiovascular disease (CVD) due to atherosclerosis is the leading cause of early mortality and morbidity. The current European guidelines on CVD prevention in clinical practice recommend the use of the Systematic Coronary Risk Estimation (SCORE) system. The current American Heart Association guidel...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2018-12, Vol.40 (12), p.2031-2040
Main Authors: Güntekin, Ünal, Gümrükçüoğlu, Hasan Ali, Yaman, Mehmet, Öztürk, Fatih, Akyol, Aytaç, Gümrükçüoğlu, Fatma Nur, Okudan, Yunus Emre, Tosun, Veysel, Kandemir, Yasemin Behram
Format: Article
Language:English
Subjects:
Arteriosclerosis
Atherosclerosis
Body mass index
Cardiology
Cardiovascular disease
Cardiovascular diseases
cardiovascular risk level
Cholesterol
Clinical medicine
Coronary artery
Coronary artery disease
Coronary vessels
Diabetes
Disease prevention
Dyslipidemia
dyslipidemia guideline
Guidelines
Health risk assessment
Health risks
Heart attacks
Heart diseases
Hypertension
Low density lipoprotein
Metabolic disorders
Morbidity
Patients
Prevention
Risk analysis
Risk assessment
Risk factors
Risk groups
Risk levels
statin
Statins
Stroke
Target recognition
Therapeutic applications
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) due to atherosclerosis is the leading cause of early mortality and morbidity. The current European guidelines on CVD prevention in clinical practice recommend the use of the Systematic Coronary Risk Estimation (SCORE) system. The current American Heart Association guidelines recommend the use of the new pooled cohort risk assessment equations to estimate the 10-year atherosclerotic CVD risk. The purpose of this article was to investigate the compliance of dyslipidemia guidelines in daily practice in patients with dyslipidemia or who have risk factors for CVD. The study group consisted of 500 outpatients who had dyslipidemia or risk factors for CVD. The risk level was computed according to the European and American Heart Association guidelines. Therapeutic LDL-C targets were identified based on the calculated risk level. Therapeutic target levels were compared based on the dosage of statins used and achievement of the LDL-C goal in daily practice according to the risk levels. According to the European dyslipidemia guidelines, 231 patients were in the very-high/high-risk group, and 106 patients (45.9%) achieved the LDL-C target (
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2018.10.002